

Qingran Yan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3727430/publications.pdf>

Version: 2024-02-01

17
papers

197
citations

1307594

7
h-index

1281871

11
g-index

17
all docs

17
docs citations

17
times ranked

336
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting miR-155 to Treat Experimental Scleroderma. <i>Scientific Reports</i> , 2016, 6, 20314.	3.3	59
2	Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. <i>Arthritis Research and Therapy</i> , 2019, 21, 92.	3.5	32
3	Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice. <i>PLoS ONE</i> , 2014, 9, e108273.	2.5	27
4	High incidence and mortality of <i>Pneumocystis jirovecii</i> infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. <i>Arthritis Research and Therapy</i> , 2021, 23, 232.	3.5	21
5	Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease. <i>Clinical Rheumatology</i> , 2016, 35, 117-125.	2.2	16
6	Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study. <i>Arthritis Research and Therapy</i> , 2020, 22, 65.	3.5	12
7	Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. <i>Clinical Rheumatology</i> , 2016, 35, 333-340.	2.2	11
8	Association of Cytomegalovirus Infection With Anti-MDA5 Antibody-Positive Dermatomyositis: A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 740154.	2.6	6
9	Dihydroartemisinin alleviates skin fibrosis and endothelial dysfunction in bleomycin-induced skin fibrosis models. <i>Clinical Rheumatology</i> , 2021, 40, 4269-4277.	2.2	5
10	Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches. <i>Current Rheumatology Reports</i> , 2020, 22, 77.	4.7	3
11	Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study). <i>Trials</i> , 2021, 22, 530.	1.6	3
12	THU0355â€¦IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP. , 2019, , .		1
13	Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. <i>Archives of Rheumatology</i> , 2020, 35, 180-188.	0.9	1
14	AB0697â€¦LOW DOSE CYCLOPHOSPHAMIDE AND PIRFENIDONE MIGHT WORK IN SYNERGY TO RELIEVE INTERSTITIAL LUNG DISEASE WITH CONNECTIVE TISSUE DISEASE: A PRELIMINARY OBSERVATIONAL STUDY. , 2019, , .		0
15	FRI0216â€¦IGURATIMOD MIGHT BE AN ALTERNATIVE OPTION FOR REFRACTORY LUPUS NEPHRITIS: A PRELIMINARY OBSERVATIONAL STUDY. , 2019, , .		0
16	39â€¦Myocardial impairment assessed by cardiac magnetic resonance in newly onset lupus patients. , 2019, , .		0
17	Improving nail involvement in systemic sclerosis: an overlooked sign in follow-up?. <i>Rheumatology</i> , 2021, , .	1.9	0